210
The results from the present study suggest that tissue plasminogen activator treatment appears to be safe in patients with acute ischemic stroke taking warfarin with an international normalized ratio <1.7 and may reduce the risk of poor functional outcome.
 patients with acute ischemic stroke: Subject; may reduce the risk of poor functional outcome: Effect; taking warfarin with an international normalized ratio <1.7: Treatment; tissue plasminogen activator treatment: Treatment; acute ischemic stroke: Treatment.Disorder; tissue plasminogen activator: Treatment.Drug; warfarin: Treatment.Drug; tissue plasminogen activator: Combination.Drug; warfarin: Combination.Drug
Given event type and trigger, please tell me the arguments of all the listed option. Output format is "name1: role1; name2: role2". 
Event type: potential therapeutic event 
  Option: Treatment.Freq, Subject.Population, Combination.Drug, Subject.Gender, Treatment.Duration, Subject, Effect, Treatment, Treatment.Disorder, Treatment.Time_elapsed, Subject.Disorder, Subject.Race, Treatment.Route, Treatment.Dosage, Subject.Age, Treatment.Drug 
Text: {0} 
Answer:
 patients with acute ischemic stroke: Subject; may reduce the risk of poor functional outcome: Effect; taking warfarin with an international normalized ratio <1.7: Treatment; tissue plasminogen activator treatment: Treatment; acute ischemic stroke: Treatment.Disorder; tissue plasminogen activator: Treatment.Drug; warfarin: Treatment.Drug; tissue plasminogen activator: Combination.Drug; warfarin: Combination.Drug